<DOC>
	<DOCNO>NCT01355952</DOCNO>
	<brief_summary>The aim study collect pilot data compare effectiveness treatment Alpha Lipoic Acid ( ALA ) reduction body weight 40 obese outpatient schizophrenia schizoaffective disorder open-label pilot trial . The investigator also plan test feasibility utilize ALA weight loss agent obese outpatient schizophrenia schizoaffective disorder term tolerability , schizophrenia symptom , cognition side effect . We run total 12 non-diabetic participant recruit diabetic patient hop compare two group .</brief_summary>
	<brief_title>An Open-Label Pilot Trial Alpha Lipoic Acid ( ALA ) Weight Loss Schizophrenia</brief_title>
	<detailed_description>Design : This ten week open-label , fix dose clinical study alpha lipoic acid ( ALA ) treatment antipsychotic weight gain outpatient schizophrenia schizoaffective disorder . Study Endpoints : The primary outcome measure change body weight baseline . Secondary outcome measure fast serum glucose , glycosylated hemoglobin , insulin , LDL cholesterol , triglyceride level , quality life ( Q-LES-Q ) , Clinical Global Impression ( CGI ) score performance The Brief Assessment Cognition Schizophrenia neurocognitive battery ( BACS ) . ( preliminary analysis , change cognitive assessment DSST task . The investigator also go conduct exploratory analyse food craving , food preference food frequency . Subjects : Subjects recruit Psychosis Program clinician referral team CMHC . Based previous weight loss study investigator expect high enthusiasm subject . Procedure assessment schedule : Subjects meet inclusion/exclusion criterion participate multi-step screening process demographic information gather , weight BMI measure fast blood take , female , urine sample test pregnancy . If lab result adequate , subject continue baseline visit start take alpha lipoic acid ( ALA ) 600mg three time day ( 1800mg total ) total ten week . At visit , weight obtain , schedule blood drawn study rating conduct . A short visit physician every two week ensure safety improve rating fidelity . Medication compliance ensure pill count , feedback encouragement standard clinical trial schizophrenia patient . Research scale standard schizophrenia food scale .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>1 . Age 18 70 year ; 2 . Meet DSMIV criterion schizophrenia schizoaffective disorder ( confirmed clinical chart ) 3 . Overweight , define BMI equal great 27 kg/mÂ² ; 4 . Be stable dose antipsychotic medication ; i.e . least one month dosage change , two month antipsychotic switch ; 5 . Deemed symptomatically stable clinical staff last two month ; 8 ) English speak 1 . A history dementia , mental retardation neurological disorder may interfere study rating ; 2 . Not capable give informed consent participation study ; 3 . Ongoing pregnancy ; 4 . A medical disorder know cause obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Alpha Lipoic Acid</keyword>
</DOC>